Female Sencar mice (6 weeks old) were administered 1 mg of 7,12-dimethylbenz[a]anthracene (DMBA) by oral gavage once a week for 5 weeks. At 20 weeks after the first dose of DMBA, 68% of mice developed mammary tumors (the average 1.08 tumors per mouse) and 45% had lymphomas/ leukemias. Feeding 1% dibenzoylmethane (DBM) in AIN 76A diet, starting at 2 weeks before the first dose of DMBA and continuing until the end of the experiment, inhibited both the multiplicity and incidence of DMBA-induced mammary tumor by 97%. The incidence of lymphomas/ leukemias was completely inhibited by 1% DBM diet. In contrast, feeding 2% curcumin diet had little or no effect on the incidence of mammary tumors, and the incidence of lymphomas/leukemias was reduced by 53%.
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Laboratory animal studies as well as human epidemiological studies both indicate that dietary habits play an important role in the development of cancer (1) (2) (3) . Several dietary phytochemicals, food substances and some drugs inhibit different stages of carcinogenesis in several animal models (3) , and some of these substances are thought to retard formation of certain human cancers in high risk populations (4) (5) (6) .
Curcumin (diferuloylmethane; structure shown in Figure 1 ) is a dietary pigment responsible for the yellow color of curry, turmeric and mustard, and it possesses high antioxidant and anti-inflammatory activities (7, 8) . Topical application of curcumin to the backs of mice inhibited benzo[a]pyrene (B[a]P)-or 7,12-dimethylbenz[a]anthracene (DMBA)-induced tumor initiation in mouse epidermis (9) . Topical application of curcumin to backs of mice previously initiated with DMBA also inhibited TPA-induced tumor promotion in mouse skin (10) . Studies in our laboratory and by others showed that topical or dietary administration of curcumin strongly inhibited tumor formation in skin, forestomach, duodenum, colon and oral cavity of rodents (9-13), whereas feeding curcumin in the diet had little or no effect on the formation of lung and breast cancers (14) . The lack of a strong chemopreventive activity of curcumin in lung and breast is thought to be due to its poor bioavailability in vivo.
Dibenzoylmethane (DBM; structure shown in Figure 1 ) is We first compared the in vitro antioxidant activity and freeradical scavenging activity of curcumin and DBM. Antioxidant activity of curcumin and DBM was measured by the Rancimat method and their free radical-scavenging activity by the 2,2Ј-diphenyl-1-picrylhydrazyl (DPPH) method (16) . DBM (98% purity) was obtained from Aldrich (Milwaukee, WI), curcumin (turmeric type 97; containing about 77% curcumin, 17% demethoxycurcumin and 3% bisdemethoxycurcumin) was obtained from Kalsec (Kalamazoo, MI). Pure lard and 2,2Ј-diphenyl-1-picrylhydrazyl (DPPH) were purchased from Sigma (St Louis, MO). The antioxidant activity (based on time for in vitro lard oxidation) of curcumin and DBM are summarized in Table I . The antioxidant indices for the vehicle, curcumin or DBM were 1.0, 5.3 or 1.0, respectively. Scavenging effects of curcumin and DBM on DPPH radicals are also shown in Table I . These in vitro assays showed that curcumin exhibited strong antioxidant and scavenging free radical activities, but DBM was essentially inactive.
Our preliminary studies showed that DBM had strong antiinflammatory and anti-tumor promoting activities in mouse skin. Topical application of DBM to mouse skin inhibited both TPA-induced skin inflammation and 7,12-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumor promotion in a dosedependent manner (unpublished results). A single topical application of 1 µmol DBM together with TPA (0.5 nmol) inhibited TPA-induced edema of mouse ears by 78%. Topical application of 10 µmol of DBM together with TPA (5 nmol) twice weekly for 20 weeks to the backs of mice previously treated with DMBA inhibited TPA-induced skin tumor promotion by 94%. Although DBM had little or no antioxidant activity in vitro, DBM showed strong anti-inflammatory and anti-tumor promoting activities in vivo, and these activities were comparable with curcumin (10) .
We then compared the chemopreventive effects of dietary curcumin and DBM on DMBA-induced mammary tumorigenesis in Sencar mice. Female Sencar mice were used in this study because DMBA can induce mammary tumors in this mouse strain in a short period of time (17) . Based on our preliminary short-term study with DBM for its effect on animal weight, a 1% DBM was chosen for our long-term chemoprevention study. The mice were administered 1 mg DMBA (in 0.1 ml corn oil) by oral gavage once a week for 5 weeks and AIN 76A diet, 2% curcumin in AIN 76A diet or 1% DBM in AIN 76A diet were given to mice starting at 2 weeks before the first dose of DMBA. At 20 weeks after To determine the effect of test compound on lard oxidation, curcumin or DBM (2 µmol in 50 µl of 40 mM aqueous methanol) was incubated with 2.5 g of lipid (pure pork lard stripped of natural antioxidants) at 110°C for 5-10 h. Air (20 ml/min) was blown through the samples. Antioxidant index is defined as the time for lipid oxidation in the presence of antioxidant compared with the control. To determine the ability of curcumin or DBM in scavenging DPPH free radical, curcumin or DBM (40 µM) was incubated with 0.1 mM DPPH in methanol. The reaction mixtures were shaken vigorously in air and then kept in the dark for 30 min. The absorption of the resulting solutions was measured in 1 cm cuvettes using a Milton Roy 301 spectrophotometer at 517 nm against the control mixture (without DPPH). All tests were run in triplicate assays. Data represent the means Ϯ SE from triplicate assays. a Statistically different from the vehicle group (P Ͻ 0.001) by the Student's t-test.
the first dose of DMBA, 68% of mice developed mammary tumors ( Figure 2A ) with an average of 1.08 mammary tumors per mouse (data not shown). Feeding 1% DBM diet starting at 2 weeks before the first dose of DMBA and continuing until the end of the experiment (the entire experimental period) inhibited the incidence of DMBA-induced mammary tumors by 97% (Figure 2A ). The multiplicity of DMBA-induced mammary tumors was also inhibited by 97% (data not shown).
In contrast, feeding 2% curcumin diet had little or no effect on DMBA-induced mammary tumorigenesis ( Figure 2A ). All tumors were examined histopathologically. Mammary tumors were classified according to the histological classification criteria described by Dunn and Sass (18) . One fibroadenoma, 13 adenocarcinomas (type B), 24 adenosquamous carcinomas and five undifferentiated carcinomas were found in the DMBA-treated mice fed the control AIN 76A diet group (Table II) . Feeding 1% DBM diet inhibited formation of the total number of carcinomas per mouse by 98%. Feeding 2% curcumin diet somewhat increased the formation of fibroadenomas and adenocarcinoma type A (not statistically significant), but inhibited the formation of adenocarcinoma type B, adenosquamous carcinomas and undifferentiated carcinomas (Table II) .
At 20 weeks after the first dose of DMBA, 45% of mice developed lymphomas/leukemias ( Figure 2B ). Feeding 1% DBM diet starting at 2 weeks before the first dose of DMBA and continuing until the end of the experiment completely inhibited the formation of lymphomas/leukemias ( Figure 2B ). Feeding 2% curcumin diet reduced the incidence of lymphomas/leukemias by 53% ( Figure 2B ). Treating Sencar mice with a high dose of DMBA (1 mg of DMBA once a week for 5 weeks) not only caused formation of mammary tumors and lymphomas/leukemias, but this treatment also produced ovarian tumors and uterine tumors. At 20 weeks after the first dose of DMBA, 20% of mice developed ovarian tumors ( Figure 2C ) and 5% had uterine tumors (two tumors per 40 mice; data not shown). Ovarian and uterine tumors were not found in the 1% DBM-treated group. Feeding 2% curcumin diet inhibited the incidence of ovarian tumors by 60% ( Figure 2C ) and completely blocked the formation of uterine tumors (data not shown). The number of uterine tumors were too small to be statistically significant. The effect of DMBA administration and long-term feeding 
Tissues were fixed in 10% buffered-formalin solution for 18-24 h, dehydrated and processed for paraffin embedding, and 4-µm sections were stained with hematoxylin-eosin. Buffered formalin-phosphate (10% formalin in neutral phosphate buffer) was purchased from Fisher Scientific (Springfield, NJ). DMBAinduced mammary tumors in Sencar mice were histopathologically classified into fibroadenoma, adenocarcinoma type A, adenocarcinoma type B, adenosquamous carcinoma and undifferentiated carcinoma. of 2% curcumin diet or 1% DBM diet on the body weight of Sencar mice is shown in Table III . Group 2 (DMBA-treated mice fed an AIN 76A diet) had a significantly decreased body weight in comparison with the vehicle-treated control group. Twenty-two weeks after the mice were treated with DMBA, the average body weight was decreased by 16% from 49.9 g (group 1) to 41.9 g (group 2). Feeding 2% curcumin diet to DMBA-treated mice for 22 weeks slightly decreased body weight (41.9 g in group 2 and 40.2 g in group 3). However, feeding 1% DBM diet further reduced body weight by 8.6% from 41.9 g in group 2 to 38.3 g in group 4 (P Ͻ 0.05). Twenty weeks after the mice were treated with DMBA (1 mg once a week for 5 weeks), there was an increase in the average liver weight from 2.02 g (group 1) to 2.17 g (group 2) and an increase in uterine weight from 0.20 g (group 1) to 0.36 g (group 2). After 22 weeks of feeding mice with 2% curcumin diet or 1% DBM diet the average liver weight was increased by 12 or 18%, respectively, and the average uterine weight was decreased by 39 or 56%, respectively (Table III) . Oral administration of 2% curcumin diet or 1% DBM diet to DMBA-treated mice inhibited the DMBA-induced increases in uterine weight, but further increased DMBA-induced increases in liver weight.
The results of our present study showed that dietary DBM markedly inhibited DMBA-induced mammary tumorigenesis in Sencar mice. Dietary DBM also strongly inhibited DMBAinduced formation of ovarian tumors and lymphomas/ leukemias in these animals. Dietary curcumin, however, had little or no inhibitory effect on DMBA-induced mammary tumorigenesis, and was less effective in inhibiting DMBA-induced formation of ovarian tumors and lymphomas/ leukemias. Our data showed that curcumin has high antioxidant activity, but DBM has little or no antioxidant activity in vitro, suggesting that the in vitro antioxidant activity is not correlated with the in vivo anti-inflammatory activity, the anti-tumor promoting activity and the anti-carcinogenic activity. Since the dose of DMBA used in this study was considerably high, the mice not only developed mammary tumors in a very short period of time after carcinogen treatment, but the animals also developed ovarian tumors, uterine tumors and lymphomas/ leukemias. Qing et al. (19) recently reported that Sencar mice intubated with 0.02 mg of DMBA once a day for 5 days per week for 6 weeks developed a 70-80% mammary tumor incidence and the incidence of lymphomas/leukemias was Ͻ5% (18) . It would be of interest to also examine the effect of dietary curcumin and DBM on mammary tumorigenesis using a low dose of DMBA.
The underlying mechanism(s) of DBM for chemopreventive activity of carcinogenesis is not yet clear. Our preliminary studies indicated that dietary DBM increases the oxidation and conjugation metabolism of endogenous estrogens and reduces their hormonal activity in target organs (uterus and mammary gland). It is unlikely that the body weight loss during feeding with DBM diet may play a critical role in inhibition of DMBAinduced mammary tumorigenesis, since there was no significant difference in the body weight between the curcumin-and DBM-treated groups. The potent inhibitory activity of DBM in DMBA-induced carcinogenesis as observed in our present study suggests that more studies of its efficacy as a cancer chemopreventive agent and its mechanism of action are needed.
